Yujun Xu

Yujun Xu

Auto-generated profile, based on publicly available information

Yujun Xu

Institute of Medical Informatics, Biometry, and Epidemiology, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in International Journal of Medical Sciences
Verified
Journal Article
Open access
XLXinghan Liu
Xinghan Liu
YXYujun Xu
Yujun Xu
YLYi Li
Yi Li
YPYuchen Pan
Yuchen Pan
SZShuli Zhao
Shuli Zhao
YHYayi Hou
Yayi Hou
Background: Regulating the polarization of macrophages to antitumor M1 macrophages is a promising strategy for overcoming the immunosuppression of the tumor microenvironment for cancer therapy. Ferumoxytol (FMT) can not only serve as a drug deliver agent but also exerts anti-tumor activity. β-glucan has immuno-modulating properties to prevent tumor growth. Thus, a nanocomposite of FMT surface-coated with β-glucan (FMT-β-glucan) was prepared to explore its effect on tumor suppression.

29 December 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
RIRolf Issels
Rolf Issels
SBStefan Boeck
Stefan Boeck
UPUwe Pelzer
Uwe Pelzer
UMUlrich Mansmann
Ulrich Mansmann
PGPirus Ghadjar
Pirus Ghadjar
JWJens Werner
Jens Werner

16 April 2022 in Human Genetics
Verified
Journal Article
Open access
PDF file
YXYujun Xu
Yujun Xu
UMUlrich Mansmann
Ulrich Mansmann
Reproducibility is not only essential for the integrity of scientific research but is also a prerequisite for model validation and refinement for the future application of predictive algorithms. However, reproducible research is becoming increasingly challenging, particularly in high-dimensional genomic data analyses with complex statistical or algorithmic techniques. Given that there are no mandatory requirements in most biomedical and statistical journals to provide the original data, analytical source code, or other relevant materials for publication, accessibility to these supplements naturally suggests a greater credibility of the published work. In this study, we performed a reproducibility assessment of the notable paper by Gerstung et al. (Nat Genet 49:332–340, 2017) by rerunning the analysis using their original code and data, which are publicly accessible. Despite an open science setting, it was challenging to reproduce the entire research project; reasons included: incomplete data and documentation, suboptimal code readability, coding errors, limited portability of intensive computing performed on a specific platform, and an R computing environment that could no longer be re-established. We learn that the availability of code and data does not guarantee transparency and reproducibility of a study; paradoxically, the source code is still liable to error and obsolescence, essentially due to methodological and computational complexity, a lack of reproducibility checking at submission, and updates for software and operating environment. The complex code may also hide problematic methodological aspects of the proposed research. Building on the experience gained, we discuss the best programming and software engineering practices that could have been employed to improve reproducibility, and propose practical criteria for the conduct and reporting of reproducibility studies for future researchers.

25 October 2025 in United European Gastroenterology Journal
Verified
Journal Article
Open access
MVMarlies Vornhülz
Marlies Vornhülz
SSSimon Sirtl
Simon Sirtl
YXYujun Xu
Yujun Xu
SKSarah Klauss
Sarah Klauss
EOElisabeth Orgler‐Gasche
Elisabeth Orgler‐Gasche
GBGeorg Beyer
Georg Beyer
Background and Aims: Acute necrotising pancreatitis carries high mortality, especially if infected necrosis occurs. While percutaneous drainage may be required when internal drainage is not feasible, reliable guidelines for managing percutaneous drains are lacking. This study aimed to assess the common practice of percutaneous drainage therapy for infected pancreatic necrosis. Methods: This retrospective study among 29 tertiary care centres included all patients hospitalised for necrotising acute pancreatitis from 01/2016 until 12/2022 with at least one percutaneous drain. The length of hospital stay was the primary endpoint, with mortality as the secondary endpoint. Between‐group comparisons were conducted using the ratio of restricted mean survival time (RMST) after adjusting for confounders. Results: 585 patients (67% male) from 29 tertiary care centres in 15 countries in Europe, Canada and Bolivia were included in the analysis. Length of hospitalisation or mortality did not differ between the flushed ( n = 398) and non‐flushed groups (RMST ratio 1.04, p ‐value = 0.42 and RMST ratio 1.05, p ‐value = 0.1 respectively). Mortality was significantly lower in those patients who received a combination of percutaneous and internal drains (dual‐modality drainage, n = 243) as compared to those who received percutaneous drains only (RMST ratio 1.05, p ‐value = 0.01). Flushing with antibiotics as compared to saline was not associated with shorter length of hospital stay or lower mortality (RMST ratio 0.98, p ‐value = 0.78 and 0.97, p ‐value = 0.48 respectively). Conclusions: This study reveals notable differences in therapeutic concepts and flushing management for percutaneous drains. While flushing itself was not associated with a shorter length of hospitalisation or lower in‐hospital mortality, a lower mortality was observed when internal and percutaneous drainage were used in combination. Clinical Trial Registration: The study was prospectively registered in the German Clinical Trials Register (Deutsches Register Klinischer Studien, DRKS) under the registration number DRKS00032231.

27 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
YXYujun Xu
Yujun Xu
UMUlrich Mansmann
Ulrich Mansmann
Reproducibility is not only essential for the integrity of scientific research, but is also a prerequisite of model validation and refinement for future application of (predictive) algorithms. However, reproducible research is becoming increasingly challenging, particularly in high-dimensional genomic data analyses with complex statistical or algorithmic techniques. Given that there are no mandatory requirements in most biomedical and statistical journals to provide the original data, analytical source code, or other relevant materials for publication, accessibility to these supplements naturally suggests a greater credibility of published work. In this study, we performed a reproducibility assessment of the notable paper by Gerstung et al. published in Nature Genetics (2017) by rerunning the analysis using their original code and data, which are publicly accessible. Despite a perfect open science setting, it was challenging to reproduce the entire research project; reasons included coding errors, suboptimal code legibility, incomplete documentation, intensive computations, and an R computing environment that could no longer be re-established. We learn that availability of code and data does not guarantee transparency and reproducibility of a study; in contrast, the source code is still liable to error and obsolescence, essentially due to methodological complexity, lack of editorial reproducibility checking at submission, and updates of software and operating environment. Building on the experience gained, we propose practical criteria for the conduct and reporting of reproducibility studies for future researchers.

9 April 2026 in ESMO Open
Verified
Journal Article
Open access
GSG.-E. Schuebbe
G.-E. Schuebbe
YXY. Xu
Y. Xu
LLLars Lindner
Lars Lindner
DGD. Di Gioia
D. Di Gioia
SAS. Abdel-Rahman
S. Abdel-Rahman
RIR. Issels
R. Issels
The German Interdisciplinary Sarcoma Group (GISG) assessed efficacy and safety of trabectedin plus regional hyperthermia (Tr + RHT) versus trabectedin (Tr) in patients with advanced soft tissue sarcoma (STS). In this randomized, open-label, multicenter study, adults with advanced STS who had progressed after at least one line of anthracycline-based chemotherapy or were unsuited for this treatment were enrolled. Patients were randomly assigned 1 : 1 to receive Tr + RHT or Tr every 3 weeks. Stratification factors included histological subtype, prior surgery (at any time), metastatic status, and Eastern Cooperative Oncology Group performance status. The primary endpoint was progression-free survival (PFS) analyzed in the intention-to-treat (ITT) population. Between 19 December 2014 and 7 December 2021, 118 eligible patients from five GISG centers were allocated to Tr + RHT (n = 60) or Tr (n = 58). Patients received a median of three cycles [interquartile range (IQR) 2-6.2 cycles] in the Tr + RHT arm and four cycles (IQR 2-6 cycles) in the Tr arm. Median PFS was 3.0 months [95% confidence interval (CI) 2.5-5.0 months] with Tr + RHT versus 3.5 months (95% CI 2.8-5.9 months) with Tr (stratified HR 0.86, 95% CI 0.57-1.29, P = 0.459). In a Cox proportional hazards model, patients receiving five or more cycles showed a median PFS of 12.8 months (95% CI 9.8-21.0 months) with Tr + RHT versus 7.8 months (95% CI 6.0-12.6 months) with Tr (stratified HR 0.33, 95% CI 0.13-0.86, P = 0.023). Most commonly reported grade 3/4 treatment-related adverse events (AEs) were hematologic, hepatic, and infections. Treatment-related deaths were reported in three patients (5.3%) of the Tr arm. Adding RHT to trabectedin did not improve PFS. Although the study was negative, a post hoc exploratory analysis of the subgroup of patients receiving ≥5 cycles of Tr + RHT showed an improvement in PFS. The combination had a manageable safety profile, serving as the basis for a subsequent study on maintenance therapy with trabectedin or lurbinectedin plus RHT in advanced STS.